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Cardiovascular magnetic resonance imaging
Aims: Repaired tetralogy of Fallot (rtoF) patients are at risk of atrial or ventricular tachyarrhythmia and
sudden cardiac death. Risk stratiﬁcation for arrhythmia remains difﬁcult.
We investigated whether cardiac anatomy and function predict arrhythmia.
Methods: One-hundred-and-ﬁfty-four adults with rtoF, median age 30.8 (21.9–40.2) years, were studied with
a standardised protocol including cardiovascular magnetic resonance (CMR) and prospectively followed up
over median 5.6 (4.6–7.0) years for the pre-speciﬁed endpoints of new-onset atrial or ventricular tachyar-
rhythmia (sustained ventricular tachycardia/ventricular ﬁbrillation).
Results: Atrial tachyarrhythmia (n = 11) was predicted by maximal right atrial area indexed to body sur-
face area (RAAi) on four-chamber cine-CMR (Hazard ratio 1.17, 95% Conﬁdence Interval 1.07–1.28 per
cm2/m2; p = 0.0005, survival receiver operating curve; ROC analysis, area under curve; AUC 0.74 [0.66–
0.81]; cut-off value 16 cm2/m2). Atrial arrhythmia-free survival was reduced in patients with RAAi
≥16 cm2/m2 (logrank p = 0.0001). Right ventricular (RV) restrictive physiology on echocardiography
(n = 38) related to higher RAAi (p = 0.02) and had similar RV dilatation compared with remaining pa-
tients.
Ventricular arrhythmia (n = 9) was predicted by CMR RV outﬂow tract (RVOT) akinetic area length (Haz-
ard ratio 1.05, 95% Conﬁdence Interval 1.01–1.09 per mm; p = 0.003, survival ROC analysis, AUC 0.77
[0.83–0.61]; cut-off value 30 mm) and decreased RV ejection fraction (Hazard ratio 0.93, 95% Conﬁdence
Interval 0.87–0.99 per %; p = 0.03). Ventricular arrhythmia-free survival was reduced in patients with
RVOT akinetic region length >30 mm (logrank p = 0.02).
Conclusion: RAAi predicts atrial arrhythmia and RVOT akinetic region length predicts ventricular arrhyth-
mia in late follow-up of rtoF. These are simple, feasible measurements for inclusion in serial surveillance
and risk stratiﬁcation of rtoF patients.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Repaired tetralogy of Fallot (rtoF) patients are a growing popula-
tion at risk of right ventricular (RV) dilatation and dysfunction, atrial
and ventricular tachyarrhythmias and sudden cardiac death during
late follow-up [1–6]. The onset of atrial or ventricular arrhythmia
in this population is associated with signiﬁcant morbidity and death
making prediction of arrhythmia a clinical priority. Currently, risk
stratiﬁcation for sudden death in adults is mainly centred aroundmedical Research Unit, Royal
ey Street, London SW3 6NP,
20 7351 8816.
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Ireland Ltd. Open access under CC BYQRS duration and impaired left ventricular function [2,3,7–9]. Previ-
ous studies investigating an association between these and other
parameters and clinical events have tended to be retrospective or
cross-sectional [4,5,9–12]. Indications and optimal timing for treat-
ments that may modify risk of arrhythmia, such as pulmonary
valve replacement (PVR) [13–15], atrial ablation, and/or prophylac-
tic automated internal cardiac deﬁbrillator implantation, are still
evolving [9,16–18]. Precise outcome prediction, however, remains
difﬁcult.
We therefore examined predictors of atrial and ventricular tachy-
arrhythmias in rtoF patients in a prospective, longitudinal study. In
the sub-group of patients with RV restrictive physiology relatively
reduced ventricular dilatation and better exercise capacity have been
demonstrated compared with others [19]. Hence, we tested whether
this subgroup behaved differently with regard to arrhythmia.-NC-ND license.
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2.1. Study design and clinical outcomes
Between 2002 and 2008, 154 rtoF patients underwent CMR and same day clinical
evaluation as part of prospective clinical research approved by the local research ethics
committee and patients gave written informed consent [20,21]. Pre-speciﬁed clinical
endpoints of new-onset atrial or ventricular arrhythmia were collected during
follow-up until December 2011. Hospital records are updated routinely by the national
death registry, thus mortality was comprehensively collected. Patients with an episode
of atrial tachyarrhythmia (AA) prior to the baseline clinical assessment were excluded
from the analysis of new-onset arrhythmia and patients were excluded from further
follow-up from the time of PVR given the propensity of intervention to alter cardiac mor-
phology and function.
2.2. Deﬁnitions of clinical endpoints
New-onset AA was deﬁned as clinically documented sustained atrial tachyarrhythmia
(atrial ﬂutter or ﬁbrillation; paroxysmal or established). New-onset ventricular tachyar-
rhythmia (VA) was deﬁned as sustained ventricular tachycardia (≥30 s), ventricular tachy-
cardia associated with presyncope or syncope (loss of consciousness clinically consistent
with cardiac cause) or ventricular ﬁbrillation. Sudden cardiac death was deﬁned as any
death clinically presumed to be related to arrhythmia.
2.3. Baseline evaluation
All cardiovascular magnetic resonance (CMR) measurements were made blinded
from the presence of arrhythmia. At recruitment all scans were conducted and analysed
by the same observer (SVB-N; interscan intraobserver coefﬁcient of variability: RVEF
1.5%/LVEF 2.1%) [22] to maximise reproducibility of measurements using a 1.5 T scanner
(Siemens Sonata, Erlangen, Germany) following a standardised protocol as previously
reported [20,21]. The contour of the right atrium (RA) was manually traced by a single
observer (BB) in the four-chamber view excluding the RA appendage and the vena
cavae at their junction with the RA. The maximum contoured area, just prior to atrioven-
tricular valve opening, was chosen to quantify the RAmaximal area indexed to body sur-
face area (RAAi) (Fig. 1A). The akinetic area length was measured by a single observer
(SBN) as we previously described [18]. The RV was imaged in at least three long axis as
well as the short axis planes. The maximum linear extent of the non-contractile region
was identiﬁed in one or more CMR planes throughout the cardiac cycle. It was usually
best measured in the sagittal RVOT view (Fig. 1B).
Interobserver variability and intraobserver variability for RAAi and RVOT akinetic
area length were tested in a sample of 20 patients by two observers (BB, AK or BB,
SBN respectively) blinded to each other.
Mean QRS duration was analysed manually from standard 12-lead electrocardiograms.
Echocardiographic pulsed and continuous wave Doppler pulmonary ﬂow velocities
were digitally recorded by a single echocardiologist (WL) using a Hewlett Packard
Sonos 7500 (Andover, Massachusetts, USA).
RV restrictive physiology was deﬁned as laminar anterograde ﬂow in the pulmo-
nary artery in late diastole coinciding with atrial contraction and present through-
out the respiratory cycle (the “a” wave) [19]. Measurements were made with
simultaneous respiratory motion recordings as previously described [19,23,24].
Tricuspid regurgitation (TR) was graded according to the European Association of
Echocardiography [25].
Peak oxygen uptake (peak VO2, mL/min/m2) was determined frombaseline cardio-
pulmonary exercise testing using graded treadmill exercise until exhaustion.Fig. 1. Measurement of maximal RAAi (A) and RVOT akinetic region length (B). Measurem
enlarged RA (33 cm2/m2). B shows a 45 mm non-contractile thin RVOT akinetic length. Ab
atrium, RV: right ventricle.The authors are solely responsible for the design and conduct of this study, analyses
and its ﬁnal contents.
2.4. Statistical methods
Continuous data are presented as mean ± standard deviation or median and
interquartile range depending on the data distribution as tested with the Kolmogorov–
Smirnov test. Comparisons between subgroups were performed by unpaired T-test,
Mann–Whitney U test or Chi-square test as appropriate. Interobserver agreement and
intraobserver agreement of CMR RAAi measurement were assessed by coefﬁcient of var-
iability. The relationship between variables and outcome was investigated by univariate
and, where appropriate, multivariate Cox proportional-hazard analysis. The results of
the Cox regression were further assessed using a non-parametric random survival forest
(RSF) analysis based on a log-rank splitting rule and time dependent receiver operator
curve (ROC) analysis based on Kaplan–Meier methodology (RSF and survival ROC pack-
age) [26]. Cut-off values were deﬁned according to the Youden rule.
Patients were censored at the time of PVR. For all analyses a two-tailed probability
value p b 0.05 was used as the cut-off for statistical signiﬁcance. Analyses were
performed using R version 2.13.2 (The R Foundation for Statistical Computing) and
MedCalc 12.1.4.0 (MedCalc Software, Mariakerke, Belgium).
3. Results
3.1. Baseline patient characteristics
One-hundred-and-ﬁfty-four patients were studied. Patient char-
acteristics are summarised in Table 1. Median follow-up was 5.6
(4.6–7.0) years. Nine patients (6%) had already presented with AA
and were therefore excluded from new-onset AA analysis and none
had previous VA. There were no clinical endpoints of syncope or death
during the included follow-up period. Forty-nine patientswere excluded
from follow-up from the time of PVR. At the end of the study period 3
deaths had occurred after PVR; two perioperative and one sudden
cardiac death.
Interobserver reproducibility and intraobserver reproducibility
were 7.9 ± 2% (0.4; 4.8 cm2/m2) and 5.3 ± 1.4% (−1.44; 4.2 cm2/m2)
for the RAAi respectively; and 7.4 ± 2.5% (−7.7; 6.7 mm) and 4.4 ±
1.5% (−4.5; 3.9 mm) for the akinetic region length respectively.
3.2. Predictors of atrial arrhythmia
Eleven AAs (7%) occurred in follow-up. Eight of 11 patients devel-
oped sustained atrial tachycardia, 7 of whom underwent subsequent
atrial ablation procedures documenting 6 isthmus-dependent atrial
ﬂutters (5 counter-clockwise and 1 clockwise) and 2 other scar-related
atrial tachycardias. The remaining 3 patients developed permanent
atrial ﬁbrillation. Patients who developed AA had a larger RAAi (16.6
[14.8–19.9] vs. 13.6 [11.9–15.2] cm2/m2; p = 0.0006), were olderents were made from balanced steady state free precession cine images. A shows an
breviations: LA: left atrium, LV: left ventricle, MPA: main pulmonary artery, RA: right
Table 1
Features of rtoF patients with new-onset atrial arrhythmias or sustained ventricular tachyarrhythmia.
All patients; n = 154 Atrial arrhythmia; n = 11 Ventricular arrhythmia; n = 9
Age at initial CMR study, years 30.8 [21.9–40.2] 45.0 [39.2–50.6]a 42.5 [34.9–50.2]b
Male, n, % 87 (56) 6 (56) 6 (66)
Hypertension (BP > 140 systolic), n (%) 10 (6.5) 2 (18) 3 (33)
Previous palliationc, n (%) 30 (20) 2 (18) 3 (33)
Age at repair, years 4.5 [2–8.3] 7.6 [5.4–19.4]b 12.8 [6.2–13.9]b
Transannular patch, n (%) 89 (65) 8 (72) 4 (44)
RVOT infundibular patch, n (%) 31 (23) 1 (9) 3 (33)
Conduit repair 17 (12) 1 (9) 2 (22)
NYHA ≥ II, n (%) 20 (13) 4 (36)a 2 (22)
QRS duration, ms 147 ± 24.6 153 ± 23 150.8 ± 29.8
QRS >180 ms, n (%) 9 (6) 1 (9) 2 (22)
PS, m/s 2 [1.5–2.6] 1.5 [1.4–2.3] 2 [1.4–3.3]
PRF, % 27.9 ± 17 20 ± 12.8 28.3 ± 15
Previous PVR, n (%) 32 (21) 2 (18) 0 (0)
Peak VO2, % of predicted 75.6 [64–88] 71 [61–80] 74 [71–77]
VE/VCO2 slope 29.7 [25–35] 34 [32–38] 34.4 [26.7–40.2]
Restrictive physiology, n (%) 38 (25) 6 (54) 0.05 3 (33)
More than mild TR, n (%) 14 (9) 4 (36)a 0
RAAi, cm2/m2 14 [12–15.4] 16.6 [14.8–19.9]a 14.6 [14–17]
RVEDVi, mL/m2 127 [102–148] 130 [115–144] 154 [123–167]
RVESVi, mL/m2 58 [45–75] 67.5 [60.9–76.2] 81 [59–94]
RVSVi, mL/m2 66 [55–76] 71 [50–75] 59 [44–76]
RVEF, % 53 [47–58] 48 [43–54] 42 [40–52]b
RVOT akinetic region length, mm 30 [20–40] 40 [27–49] 55 [34–60]a
LVEDVi, mL/m2 73 [64–85] 78 [66–96] 100 [69–112]
LVESVi, mL/m2 26 [21–33] 26 [22–33] 41 [18–52]
LVSVi, mL/m2 47 [41–56] 49 [40–57] 59 [39–62]
LVEF, % 64 [60–70] 63 [59–72] 62 [51–68]
LVEF b45%, n (%) 5 (3) 2 (18)d 1 (0.6)
Data are expressed as mean ± standard deviation or median [IQR] as appropriate. CMR: cardiac magnetic resonance imaging, ECG: electrocardiography, LVEDVi: left ventricular
end-diastolic volume indexed, LVEF: left ventricular ejection fraction, LVESVi: left ventricular end-systolic volume indexed, LVSVi: left ventricular stroke volume indexed, n: number
of patients, NYHA: New York Heart Association, PRF: pulmonary regurgitant fraction, PS: pulmonary stenosis, PVR: pulmonary valve replacement, RA: right atrium, RAAi: maximum
right atrial area indexed, rtoF: repaired tetralogy of Fallot, RVEDVi: right ventricular end-diastolic volume indexed, RVEF: right ventricular ejection fraction, RVESVi: right ventricular
end-systolic volume indexed, RVOT: right ventricular outﬂow tract, RVSVi: right ventricular stroke volume indexed, TR: tricuspid regurgitation, VT: ventricular tachycardia. Statistically
signiﬁcant results are formatted bold.
a Signiﬁcant difference (p ≤ 0.01) between this subgroup and remaining patients.
b Signiﬁcant difference (p b 0.05) between this subgroup and remaining patients.
c 19 previous Blalock–Taussig shunt, 8 previous Waterston shunt and 6 Brock procedures.
d Trend with p = 0.05 for difference between this subgroup and remaining patients.
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repair (7.6 [5.4–19.4] vs. 4.4 [1.9–8.4] years; p = 0.02), were in
worse functional class (New York Heart Association Class ≥ II: 36
vs. 13%; p = 0.01) and more often had TR (>mild TR: 36 vs. 9%;
p = 0.0006) (Table 1). RAAi, age at baseline, age at repair, and more
than mild TR were signiﬁcant predictors of AA on univariate Cox anal-
ysis and random survival forest analysis (Table 2, Fig. 2). In view of the
number of events and number of univariate predictors, random survival
forest analysis was chosen rather thanmultivariate stepwise regression
Cox analysis and RAAi was the strongest predictor of new-onset AA
(Fig. 2). On ROC analysis, a cut-off value of 16 cm2/m2 was found to
predict new-onset AA with sensitivity and speciﬁcity of 66% and 86%
respectively, with area under the curve (AUC) of 0.75, during a median
follow-up of 5.6 years.
RAAi ≥16 cm2/m2 predicted reduced AA-free survival (logrank
p = 0.0001) (Fig. 3A).
3.3. Restrictive physiology and atrial arrhythmia
Features of RV restrictive physiology in rtoF patients are summarised
in Table 3. Restrictive RV physiology patients had a larger RA size
(p = 0.02), were older (p = 0.03), had a later repair (p = 0.02),
and more often had TR (>mild TR; p = 0.0002) compared with the
remaining patients; these parameters were predictors of new-onset
AA. There was a trend towards restrictive RV physiology itself relating
to new-onset atrial tachyarrhythmia (p = 0.057). RAAi was correlated
signiﬁcantly with RV end-diastolic volume index (r = 0.4, p b 0.0001)
and inversely with RV ejection fraction (r = −0.4, p b 0.0001).3.4. Predictors of ventricular arrhythmia in follow-up
Nine (6%) patients had VA during follow-up. These patients
consisted of 3 patients with syncope due to sustained ventricular
tachycardia, 1 patient with witnessed presyncope due to ventricular
tachycardia, 4 patients with haemodynamically tolerated sustained
ventricular tachycardia >30 s and 1 patient presenting with out-of-
hospital cardiac arrest with ventricular ﬁbrillation requiring DC car-
dioversion. Patients who developed VA were older (42.5 [34.9–50.2]
vs. 29 [21–40] years; p = 0.01), had a later repair (12.8 [6.2–13.9]
vs. 4.4 [2–8] years; p = 0.02), larger akinetic RVOT region (length
55 [34–60] vs. 30 [20–40] mm; p = 0.002) and a lower RV ejection
fraction (42 [40–52] vs. 53 [51–55] %; p = 0.01) (Table 1). On univar-
iate Cox analysis, only the RVOT akinetic region length and RV ejection
fraction were predictive of VA (Table 2). On stepwise Cox regression
analysis, the RVOT akinetic region length was the only remaining pre-
dictor of VA (Hazard ratio 1.05, 95% Conﬁdence Interval 1.01–1.08 per
mm; p = 0.004). The survival ROC curve analysis indicated a cut-off
value of 30 mm as a predictor of VA during a median follow-up of
5.6 years with AUC of 0.77, sensitivity of 83% and speciﬁcity of 61%.
RVOT akinetic area length >30 mm predicted reduced VA-free
survival (logrank p = 0.02) (Fig. 3B).
4. Discussion
To our knowledge this is the ﬁrst prospective, longitudinal clinical
study demonstrating the predictive value of RA size and RVOT mor-
phology for atrial and ventricular tachyarrhythmias in adults with
Table 2
Univariate Cox analysis for new-onset atrial or ventricular tachyarrhythmia.
Atrial arrhythmia; n = 11 Ventricular arrhythmia; n = 9
HR 95% CI p HR 95% CI p
Age at initial CMR study, years 1.07 1.03–1.12 0.0004 1.04 0.99–1.09 NS
Age at repair, years 1.07 1.02–1.12 0.002 1.04 0.97–1.1 NS
Prior cardiac surgery, n 0.79 0.34–1.8 NS 1.40 0.57–3.49 NS
QRS duration, ms 1.01 0.98–1.03 NS 1.01 0.97–1.03 NS
PS Vmax, m/s 0.66 0.24–1.78 NS 1.30 0.58–3.17 NS
PRF, % 0.97 0.94–1.006 NS 0.99 0.95–1.03 NS
Peak VO2, mL/kg/min 0.99 0.96–1.01 NS 0.99 0.96–1.02 NS
RAAi, cm2/m2 1.17 1.07–1.28 0.0005 1.00 0.99–1.002 NS
TR >mild, n 6.7 1.9–22.9 0.002 – – –
Restrictive RV 3.3 1.01–10.8 0.04 1.10 0.26–4.49 NS
RVEDVi, mL/m2 1.002 0.98–1.01 NS 1.01 0.99–1.02 NS
RVESVi, mL/m2 1.005 0.98–1.02 NS 1.01 0.99–1.02 NS
RVEF, % 0.95 0.9–1.01 NS 0.93 0.87–0.99 0.03
Akinetic region length, mm 1.01 0.98–1.05 NS 1.05 1.01–1.09 0.003
RVMi, g/m2 0.96 0.90–1.01 NS 1.01 0.99–1.04 NS
LVEDVi, mL/m2 1.01 0.98–1.04 NS 1.02 0.99–1.05 NS
LVEF, % 0.98 0.92–1.03 NS 0.96 0.90–1.03 NS
LVSVi, mL/m2 0.99 0.94–1.05 NS 1.03 0.97–1.09 NS
CI: Conﬁdence Interval, CMR: cardiovascular magnetic resonance, HR: hazard ratio, LVEDVi: left ventricle volume indexed, LVEF: left ventricle ejection fraction, LVSVi: left
ventricular stroke volume indexed, PRF: pulmonary regurgitant fraction, PS V max: pulmonary stenosis peak velocity, RAAi: maximal right atrial area indexed, RVEDVi: right ven-
tricular end-diastolic volume, RVEF: right ventricular ejection fraction, RVESVi: right ventricular end-systolic volume indexed, RVSVi: right ventricular stroke volume indexed,
LVSVi: left ventricular stroke volume indexed, n: number of patients, RVEF: right ventricular ejection fraction, RVMi: right ventricular mass indexed, VT: TR: tricuspid regurgitation,
ventricular tachycardia, (–): insufﬁcient data for appropriate analysis. Statistically signiﬁcant p values are formatted bold.
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rospective or cross-sectional [20,27–29]. RA dilatation was highly predic-
tive of AA onset and more strongly predictive than older age, later repair
or TR. Restrictive RV physiology was associated with older age, later re-
pair, TR and larger RA, all of which in turn were associated with AA. VA
was predicted by RVOT akinetic area length and impaired RV ejection
fraction and independently predicted only by larger RVOT akinetic region.
Atrial chamber enlargement and ventricular chamber enlargement are
known drivers of adverse cardiac remodelling and arrhythmogenesis for
the left heart [30]. Our study demonstrated that right-sided morphology
is predictive of clinical arrhythmia, both atrial and ventricular, after rtoF.
4.1. Atrial tachyarrhythmia and relations to right atrial dilatation
RAAi is a feasible measurement during periodic follow-up, had
acceptable variability and was a strong predictor of outcome in rtoF
patients. A cut-off value of 16 cm2/m2 was predictive of AA.Fig. 2. Random survival forest analysis for predictors of atrial tachyarrhythmia. The
relative importance of RAAi, age at the index CMR study, increased age at repair and
the presence of more than mild TR for AA prediction during a median follow-up of
5.6 years is shown. The upper and leftward location in the plot of RAAi illustrates its
greater relative importance and the size of the circle the larger effect size. The dashed
line is the cut-off for relevant predictors. Abbreviations: CMR: cardiac magnetic reso-
nance imaging, RAAi: right atrium area indexed, TR: tricuspid regurgitation.A 7% incidence of AA was seen in our study at a median age of 45
[39.2–50.6] years over a median follow-up period of 5.6 years. Preva-
lence of AA has been reported to increase exponentially with age after
a relatively quiescent period of 10 to 15 years [1] and in rtoF patients
is associated with a high morbidity [2]. By the end of our study
follow-up there was 13% prevalence of atrial arrhythmia in keeping
with other studies [1,2]. Patients who developed AA in our study were
older with median age 45 years. Older age and later age at repair have
also been consistently noted as risk factors for atrial arrhythmias in pre-
vious studies [1,2,5,20,29].
Additionally, RA enlargementwas a stronger predictor of new-onset
AA than age or late repair in this study in which RA dilatation pre-dated
atrial rhythm disturbance. Whether atrial dilatation is a cause or a con-
sequence of rhythm disturbance has been debated [31]. Dilatation
of atrial chambers is a well-understood determinant of AA propensity
as it causes atrial stretch and consequent atrial electrical remodelling
[31,32]. In rtoF, RA dilatation and dysfunction relate to chronic pressure
or volume overload as well as previous intracardiac surgery involving
surgical atriotomy andpotentially progressive atrialmyocardialﬁbrosis.
RA distension may trigger atrial tachycardia relating to surgical atrial
scar. In a previous large, retrospective study of 793 rtoF patients, TR
was reported to be predictive of AA, presumably relating to resultant
RA dilatation leading to arrhythmogenesis [2]. Detailed data regarding
atrial substrates were not available for that cohort. RA enlargement
discretely categorised as present or absent was also suggested to be a
marker for atrial tachycardia by other investigators, though again de-
tailed atrial characterisation was unavailable [1,33]. Whilst TR and RA
dilatation are related to each other, and TR clearly predisposes to atrial
arrhythmia, our study showed that RA enlargement predicted atrial
arrhythmia more strongly than TR.
Reverse remodelling of the left atrium with intervention is associ-
ated with reduction in the risk of subsequent AA [34]. Future studies
are needed to address the potential for reverse RA remodeling with
ageing and with late intervention.
4.2. RV restrictive physiology, RA and RV dilatation
In contrast to the younger patients in previous reports [19] restric-
tive RV physiology rtoF patients had similar degree of RV dilatation,
cardiopulmonary exercise capacity, pulmonary regurgitation and QRS
Fig. 3. Kaplan–Meier curves illustrating freedom from atrial (A) and ventricular (B) tachyarrhythmias. A shows the time-to-atrial arrhythmia with respect to a RAAi cut-off value of
16 cm2/m2. B shows the time-to-ventricular arrhythmia with respect to a RVOT akinetic region length cut-off value of 30 mm. Abbreviations: n: number of patients, RAAi: maximal
right atrium area indexed, RVOT: right ventricular outﬂow tract.
3284 B. Bonello et al. / International Journal of Cardiology 168 (2013) 3280–3286duration than the remaining patients. RV restrictive physiology was
associatedwith increased RA size predisposing these patients to signif-
icant morbidity related to AA which was 3 times more common than
in those without restrictive RV physiology. The ﬁnding of a restrictive
RV physiology associated with large RV in older rtoF patients has 2
potential explanations. First, any “protective” effect of RV restrictive
physiology against RV dilatation was then not sustained over a longer
follow-upperiod. Alternatively, beyond a certain degree of RVdilatation
any further ﬁlling became limited and a restrictive physiology pattern
appeared.
4.3. Ventricular arrhythmia and RV infundibular disease
RVOT akinetic region length and decreased RV ejection fraction
predicted ventricular arrhythmia in this study. Non-contractile RVOT
regions contribute to decreased RVEF [20,27]. RVOT akinetic region
length was independently predictive of VA during follow-up. RVOT
akinetic regions have been associated with myocardial ﬁbrosis orTable 3
Features of rtoF patients with RV restrictive physiology.
Restrictive RV physiolo
n = 38
Age at initial CMR study, years 38 [26.1–45.0]
Age at repair, years 6.7 [3.8–12.8]
Transannular patch repair, n 23 (60)
QRS duration, ms 146 ± 27
PS, m/s 2.1 [1.5–3]
PRF, % 29.2 ± 14
Peak VO2, % predicted 75.6 [64–89]
Peak VO2 achieved, mL/kg/min 26.1 [20–29]
RAAi, cm2/m2 14.6 [12.7–16.6]
TR >mild, n (%) 8 (21)
Atrial arrhythmia, n, new-onset (total) 6 (15)
Ventricular arrhythmia, n, new-onset (total) 3 (7)
PVR, n, new-onset (total) 10 (26)
RVEDVi, mL/m2 125 [107–145]
RVESVi, mL/m2 59.6 [42–71]
RVSVi, mL/m2 65 [54–77]
RVEF, % 53 [48–57]
Akinetic region length, mm 30 [20–45]
RVMi, g/m2 55 ± 20
LVEDVi, mL/m2 72 [59–93]
LVSVi, mL/m2 47 [39–53]
LVEF, % 63 [58–70]
Data are expressed as mean ± standard deviation, median [IQR] and number (%) as approp
LVEDVi: left ventricle end-diastolic volume indexed, LVEF: left ventricle ejection fraction,
regurgitant fraction, PS: pulmonary stenosis, PVR: pulmonary valve replacement, RAAi:
end-diastolic volume indexed, RVEF: right ventricular ejection fraction, RVESVi: right vent
RVi mass: right ventricular mass indexed, TR: tricuspid regurgitation, VT: ventricular tachyscarring (not necessarily related to surgical patching) [20] and electro-
mechanical delay [35]. A signiﬁcant proportion, though not all, of our
patients underwent earlier era surgerywith infundibular or transannular
patch use at the time of repair. Yet, the RVOT akinetic regions seemed to
relate to ongoing risk of arrhythmia. Suture line around the RVOT patch
may vary in size and provide a perimeter between neighbouring pros-
thetic patch material and native RVOT which may be a potential nidus
for progressive stretch, thinning and distension, ongoing myocardial
ﬁbrosis and arrhythmogenesis [20]. Furthermore, electromechanical
delay in the RVOT contributes to total RV delay and prolongation of
the QRS duration [35]. QRS duration prolongation, in turn, is a major
risk factor for sudden cardiac death [2]. The source of ventricular tachy-
cardia ismost commonly the RVOT in rtoF [36,37]. The RV infundibulum
in rtoF therefore plays a key role in determining the risk of developing
clinical VT. There is further justiﬁcation, therefore, for the recentlymod-
iﬁed surgical approaches to repair of tetralogy of Fallot which aim to
limit the extent and depth of myocardial RVOT infundibular resection
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ventricular tachycardia [2] that can be addressed with PVR. To what
degree RVOT akinetic resection during PVR can further modify the
risk of ventricular arrhythmia is still unclear. PVR associated with
intraoperative cryoablation decreases the incidence of sustained ven-
tricular tachycardia [13]. In a randomised trial of PVR with RVOT patch
resection versus PVR with individualised more extensive RVOT scar
resection, no additional RV remodellingwas found at 6 months; longer
follow-upwould be required to determine a potential effect on VA pro-
pensity [39].
In contrast with previous studies, QRS duration>180 ms, pulmonary
regurgitation, and LV dysfunction did not predict sustained ventricular
tachycardia in this study [1,4,5,7]. The majority of our patients had
pulmonary regurgitation, right bundle branch block and a prolonged
QRS duration (mean 150 ms) so a much longer period of observation
may be required to detect different outcomes based on these results.
Furthermore, potentially relevant markers of LV impairment more
subtle than ejection fraction were not assessed. We do not therefore
conclude that these factors are irrelevant. However, LV dysfunction
may be a later phenomenon and be consequent to RV impairment due
to ventricular–ventricular interaction [27,28]. Therefore, RV outﬂow
tract and RV dysfunction may be of earlier prognostic value.
4.4. Study limitations
Congenital heart disease studies including ours are inherently
small, the clinical event rate per year is relatively low and thus Cox
regression analysis can be underpowered to detect all predictors.
Random survival forest analysis has been shown to outperform para-
metric methods when sample sizes are small [40]. Despite relatively
few events in long-term follow-up, this prospective study does have
the advantage of comprehensive single-centre data collection and op-
timal study design for maximising CMRmeasurement reproducibility.
A large multicentre trial or registry may validate our data and include
the potential prognostic role of other factors such as electrophysio-
logical studies and ablations [4] late gadolinium enhancement (LGE)
CMR [20] or signal averaged ECG [41] not assessed here. Despite
that the four-chamber cines were all acquired by the same operator
and according to the same protocol, RAAi measurement may depend
on the exact slice orientation. In the future, determination of RA
volume using a contiguous atrial stack of transaxial or short axis
cines might prove worthwhile. Our existing study approach however
does allow feasible measurement from routine existing protocols
without lengthening CMR duration.
Myocardial ﬁbrosis demonstrated with LGE CMR may prove to be
an important risk factor for tachyarrhythmia in rtoF as cross-sectionally
more extensive RV LGEwas shown to correlatewith clinical arrhythmia
presentation [20]. RVOT LGE corresponds to regional akinesia and
could also be measured linearly in a further prospective study. Current
rtoF patients have undergone modiﬁed surgical approaches, undergo-
ing repair at an earlier age and having operations sparing the RVOT
infundibulum [38]. Risk factors for younger adults and future adult
patients may therefore differ from those reported in this population.
Paced patients and those with primary prevention automated-internal-
cardiac-deﬁbrillator were not included in this study due to the need for
CMR.
5. Conclusions
RA area enlargement is a strong predictor of atrial tachycardia
during late follow-up of patients with rtoF. Larger RVOT akinetic re-
gion and impaired RVEF predict ventricular tachyarrhythmia. The RV
infundibulum in rtoF plays a key role in determining the risk of ven-
tricular arrhythmogenesis. These are newly described predictors of
clinical outcome. Restrictive RV physiology predisposes to RA enlarge-
ment and thus to atrial arrhythmogenesis in follow-up. Whetherchanges in RA or RVOT anatomy and function from electrophysiologi-
cal or surgical interventions canmodulate the arrhythmic risk in these
patients needs to be examined.
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